Agendia Inc. and Paige, are collaborating to co-development treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia's proprietary MammaPrint and BluePrint diagnostic tests for patients with breast cancer.
A new paper published in JNCI: Journal of the National Cancer Institute indicates that receiving assisted reproductive technology does not increase the risk women have for developing ovarian cancer.
Researchers at the UCLA Jonsson Comprehensive Cancer Center found patients with a particular type of human leukocyte antigen (HLA), a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy.
Researchers at NYU Grossman School of Medicine and Perlmutter Cancer Center trained a computer to tell which skin cancer patients may benefit from drugs that keep tumors from shutting down the immune system's attack on them.
Phase III trial data shows that a developmental drug, plinabulin, could help keep cancer patients on needed chemotherapy treatments.
Nerlynx (neratinib) demonstrates a 5.1% invasive disease-free survival benefit versus placebo in the phase III ExteNET trial evaluating Nerlynx in HER2-positive, hormone receptor-positive early stage breast cancer.
Hannah Hazard-Jenkins, associate chair of surgery for cancer services, was named the permanent director of the WVU Cancer Institute after having served in the position on an interim basis since January.
Edward S. Kim was named senior vice president and vice physician-in-chief at City of Hope, and physician-in-chief at City of Hope Orange County.
Julia H. Rowland, member of the National Coalition for Cancer Survivorship Board of Directors and former director of NCI's Office of Cancer Survivorship, and Thomas J. Smith, director of palliative medicine for Johns Hopkins Medicine, received the 2020 Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care, presented by The National Coalition for Cancer Survivorship.
Jedd Wolchok received a $1 million grant over a three-year period from The William Randolph Hearst Foundation to establish a new immuno-oncology research fellowship at Memorial Sloan Kettering Cancer Center, and support postdoctoral students who are conducting exceptional research in the field of immune-oncology and immunotherapy.
